Camptothecin - BlueLink Pharmaceuticals

Drug Profile

Camptothecin - BlueLink Pharmaceuticals

Alternative Names: CRLX 101; Cyclosert™-enhanced camptothecin; IT-101

Latest Information Update: 21 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Insert Therapeutics
  • Developer AstraZeneca; Beth Israel Deaconess Medical Center; BlueLink Pharmaceuticals; Brigham and Womens Hospital; Cerulean Pharma; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Cancer Institute (USA); University of North Carolina
  • Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase I/II Solid tumours
  • Preclinical Breast cancer
  • No development reported Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 02 Jul 2017 Phase-II clinical trials in Rectal cancer (Combination therapy, Late-stage disease, Neoadjuvant therapy) in USA (IV), before June 2017 (NCT02010567)
  • 02 Jun 2017 Interim efficacy and adverse events data from a phase Ib/II trial in Rectal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 20 Mar 2017 Cerulean enters into an agreement with BlueLink Pharmaceuticals to sell camptothecin (CRLX 101) and docetaxel (CRLX 301)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top